Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. by Bergdahl, A, Aus, G, Lilja, H, Hugosson, J

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. by Aus, G, Bergdahl, S, Lodding, P, Lilja, H, Hugosson, J

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. by Hugosson, J, Aus, G, Lilja, H, Lodding, P, Pihl, C

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. by Aus, G, Becker, C, Franzén, S, Lilja, H, Lodding, P, Hugosson, J

Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. by Zackrisson, B, Ulleryd, P, Aus, G, Lilja, H, Sandberg, T, Hugosson, J

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). by Aus, G, Becker, C, Lilja, H, Khatami, A, Pihl, C, Hugosson, J

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. by Hugosson, J, Aus, G, Lilja, H, Lodding, P, Pihl, C, Pileblad, E

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. by Aus, G, Damber, J, Khatami, A, Lilja, H, Stranne, J, Hugosson, J

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. by Zackrisson, B, Aus, G, Lilja, H, Lodding, P, Pihl, C, Hugosson, J

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostat... by Khatami, A, Aus, G, Damber, J, Lilja, H, Lodding, P, Hugosson, J

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is quest... by Zackrisson, B, Aus, G, Bergdahl, S, Lilja, H, Lodding, P, Pihl, C, Hugosson, J

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. by Hugosson, J, Aus, G, Bergdahl, S, Fernlund, P, Frösing, R, Lodding, P, Pihl, C, Lilja, H

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. by Hugosson, J, Aus, G, Becker, C, Carlsson, S, Eriksson, H, Lilja, H, Lodding, P, Tibblin, G

Prognostic value of serum markers for prostate cancer. by Stenman, U, Abrahamsson, P, Aus, G, Lilja, H, Bangma, C, Hamdy, F, Boccon-Gibod, L, Ekman, P

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate C... by Vickers, A, Cronin, A, Aus, G, Pihl, C, Becker, C, Pettersson, K, Scardino, P, Hugosson, J, Lilja, H

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. by Hugosson, J, Carlsson, S, Aus, G, Bergdahl, S, Khatami, A, Lodding, P, Pihl, C, Stranne, J, Holmberg, E, Lilja, H

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. by Vickers, A, Cronin, A, Aus, G, Pihl, C, Becker, C, Pettersson, K, Scardino, P, Hugosson, J, Lilja, H

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. by Vickers, A, Wolters, T, Savage, C, Cronin, A, O'Brien, M, Roobol, M, Aus, G, Scardino, P, Hugosson, J, Schröder, F, Lilja, H

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. by Vickers, A, Wolters, T, Savage, C, Cronin, A, O'Brien, M, Pettersson, K, Roobol, M, Aus, G, Scardino, P, Hugosson, J, Schröder, F, Lilja, H

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer,... by Khatami, A, Ali, K, Aus, G, Gunnar, A, Damber, J, Jan-Erik, D, Lilja, H, Hans, L, Lodding, P, Pär, L, Hugosson, J, Jonas, H